JP2018516969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516969A5 JP2018516969A5 JP2017564421A JP2017564421A JP2018516969A5 JP 2018516969 A5 JP2018516969 A5 JP 2018516969A5 JP 2017564421 A JP2017564421 A JP 2017564421A JP 2017564421 A JP2017564421 A JP 2017564421A JP 2018516969 A5 JP2018516969 A5 JP 2018516969A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- binding portion
- specifically binds
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 claims 34
- 102000036639 antigens Human genes 0.000 claims 34
- 108091007433 antigens Proteins 0.000 claims 34
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 21
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 201000011510 cancer Diseases 0.000 claims 12
- 230000037396 body weight Effects 0.000 claims 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 229960002621 pembrolizumab Drugs 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000003761 Vaginal carcinoma Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 208000024558 digestive system cancer Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 201000003914 endometrial carcinoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 claims 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000003911 head and neck carcinoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 102000053523 human CXCR4 Human genes 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 231100001142 manageable toxicity Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000002990 parathyroid gland Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 201000009295 smoldering myeloma Diseases 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000005747 tumor angiogenesis Effects 0.000 claims 1
- 229950010095 ulocuplumab Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 208000013013 vulvar carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562174931P | 2015-06-12 | 2015-06-12 | |
| US62/174,931 | 2015-06-12 | ||
| PCT/US2016/037207 WO2016201425A1 (en) | 2015-06-12 | 2016-06-13 | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516969A JP2018516969A (ja) | 2018-06-28 |
| JP2018516969A5 true JP2018516969A5 (enExample) | 2019-07-18 |
Family
ID=56194616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564421A Withdrawn JP2018516969A (ja) | 2015-06-12 | 2016-06-13 | Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20180179282A1 (enExample) |
| EP (1) | EP3307778A1 (enExample) |
| JP (1) | JP2018516969A (enExample) |
| CN (1) | CN108026173A (enExample) |
| BR (1) | BR112017026189A2 (enExample) |
| CA (1) | CA2989144A1 (enExample) |
| EA (1) | EA201792522A1 (enExample) |
| MX (1) | MX2017015811A (enExample) |
| WO (1) | WO2016201425A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006265108C1 (en) * | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| CA3213528A1 (en) * | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| JP6958820B2 (ja) | 2015-12-14 | 2021-11-02 | エックス４ ファーマシューティカルズ， インコーポレイテッド | がんを処置する方法 |
| CA3008272A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| SI3393468T1 (sl) | 2015-12-22 | 2023-01-31 | X4 Pharmaceuticals, Inc. | Postopki za zdravljenje bolezni imunske pomanjkljivosti |
| CN108883132A (zh) * | 2016-01-22 | 2018-11-23 | X4 制药有限公司 | 用于治疗癌症的方法 |
| WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109641838A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| EP3471726A4 (en) | 2016-06-21 | 2019-10-09 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| US20190307821A1 (en) * | 2016-11-29 | 2019-10-10 | Health Research, Inc. | Methods and compositions for cancer therapy |
| WO2018175676A1 (en) | 2017-03-23 | 2018-09-27 | The General Hospital Corporation | Cxcr4/cxcr7 blockade and treatment of human papilloma virus-associated disease |
| US20190233524A1 (en) * | 2017-09-18 | 2019-08-01 | Tcm Biotech International Corp. | Therapeutic combination and method for treating cancer |
| CN109517039B (zh) * | 2017-09-20 | 2021-03-19 | 尚华医药科技(江西)有限公司 | 一种肽类化合物、其应用及含其的组合物 |
| CA3080821A1 (en) * | 2017-11-07 | 2019-05-16 | X4 Pharmaceuticals, Inc. | Cancer biomarkers and methods of use thereof |
| ES2973728T3 (es) * | 2018-03-13 | 2024-06-24 | Fundacion Para La Investigacion Biomedica Del Hospital Univ La Paz | Anticuerpo anti-CXCR4 combinado con linfocitos citolíticos naturales activados y expandidos para inmunoterapia contra el cáncer |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CA3115802A1 (en) | 2018-10-17 | 2020-04-23 | Biolinerx Ltd. | Treatment of metastatic pancreatic adenocarcinoma |
| WO2020135415A1 (zh) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| US12497439B2 (en) | 2019-01-07 | 2025-12-16 | Thomas Jefferson University | Multi-functional fusion proteins and uses thereof |
| JP7547360B2 (ja) * | 2019-03-22 | 2024-09-09 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法 |
| JP2023517956A (ja) | 2020-03-10 | 2023-04-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 好中球減少症を処置する方法 |
| CA3247048A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE |
| KR20250004768A (ko) | 2022-04-13 | 2025-01-08 | 제넨테크, 인크. | 치료 단백질의 약학적 조성물 및 사용 방법 |
| AR129203A1 (es) * | 2022-05-04 | 2024-07-31 | Janux Therapeutics Inc | Anticuerpos multiespecíficos activados por tumores para dirigirse a cd28 y pd-l1, y métodos para usarlos |
| CN115487146B (zh) * | 2022-10-28 | 2023-07-18 | 宁夏医科大学 | 一种阻断cxcr4/pd-l1双信号的三药共递送纳米体系及其制备方法和应用 |
| WO2024120084A1 (zh) * | 2022-12-07 | 2024-06-13 | 宜明昂科生物医药技术（上海）股份有限公司 | 使用cd24抗体和pd-1-pd-l1通路阻断抗体的癌症联合疗法 |
| CN120813375A (zh) * | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| JP5244785B2 (ja) | 2006-08-11 | 2013-07-24 | 小野薬品工業株式会社 | ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体 |
| EP2066351B1 (en) | 2006-10-02 | 2015-09-09 | E. R. Squibb & Sons, L.L.C. | Human antibodies that bind cxcr4 and uses thereof |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US7892546B2 (en) | 2008-05-14 | 2011-02-22 | Eli Lilly And Company | Anti-CXCR4 antibodies |
| JP2011520885A (ja) | 2008-05-14 | 2011-07-21 | イーライ リリー アンド カンパニー | 抗ｃｘｃｒ４抗体 |
| MX2011002250A (es) * | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| EP2172485A1 (en) | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
| PT2376535T (pt) | 2008-12-09 | 2017-06-23 | Hoffmann La Roche | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| CA2842169A1 (en) | 2011-07-20 | 2013-01-24 | Medimmune Limited | Anti-cxcr4 antibodies and methods of use |
| ES2705001T3 (es) | 2011-11-09 | 2019-03-21 | Bristol Myers Squibb Co | Tratamiento de neoplasias hematológicas con un anticuerpo anti-CXCR4 |
| CA2856895C (en) | 2011-11-28 | 2021-10-26 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| CA3213528A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| EP2854843A4 (en) | 2012-05-31 | 2016-06-01 | Sorrento Therapeutics Inc | ANTIGEN-BINDING PROTEINS FOR BINDING PD-L1 |
| PL2925350T3 (pl) | 2012-12-03 | 2019-07-31 | Bristol-Myers Squibb Company | Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc |
| EP4050033A1 (en) | 2013-08-02 | 2022-08-31 | Pfizer Inc. | Anti-cxcr4 antibodies and antibody-drug conjugates |
| EP3030322A2 (en) * | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
-
2016
- 2016-06-13 BR BR112017026189A patent/BR112017026189A2/pt not_active IP Right Cessation
- 2016-06-13 EP EP16731754.4A patent/EP3307778A1/en not_active Withdrawn
- 2016-06-13 EA EA201792522A patent/EA201792522A1/ru unknown
- 2016-06-13 US US15/735,055 patent/US20180179282A1/en not_active Abandoned
- 2016-06-13 WO PCT/US2016/037207 patent/WO2016201425A1/en not_active Ceased
- 2016-06-13 CA CA2989144A patent/CA2989144A1/en not_active Abandoned
- 2016-06-13 CN CN201680047043.2A patent/CN108026173A/zh active Pending
- 2016-06-13 JP JP2017564421A patent/JP2018516969A/ja not_active Withdrawn
- 2016-06-13 MX MX2017015811A patent/MX2017015811A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516969A5 (enExample) | ||
| US11103579B2 (en) | Combination of DR5 agonist and anti-PD-1 antagonist and methods of use | |
| JP2015534577A5 (enExample) | ||
| JP6215429B2 (ja) | Ｃｄ３８を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ | |
| JP2015534578A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| JP2017514795A5 (enExample) | ||
| JPWO2021194942A5 (enExample) | ||
| CN109963592B (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| HRP20230517T1 (hr) | Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka | |
| JP2019519499A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2018027952A5 (enExample) | ||
| JP2019515008A5 (enExample) | ||
| JP2019500869A5 (enExample) | ||
| JP2018527383A5 (enExample) | ||
| JP2018534933A5 (enExample) | ||
| JP2016502504A5 (enExample) | ||
| JP2015534580A5 (enExample) | ||
| JP2018516966A5 (enExample) | ||
| JP2019503387A5 (enExample) | ||
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| JP2020515577A5 (enExample) | ||
| JP2019524714A5 (enExample) | ||
| JP2020522543A5 (enExample) |